Abstracts presented incorporate Company’s ultrasensitive AmpliMark NGS platform to analyze diverse signals in blood including mutations, methylation and T-cell receptor repertoire
VIENNA–(BUSINESS WIRE)–Lucence will present new data at the upcoming IASLC 2022 World Conference on Lung Cancer on August 6-9, 2022, highlighting novel applications of its ultrasensitive amplicon-based next generation sequencing technology in the detection and treatment of lung cancer.
“Liquid biopsy will continue to transform the way we diagnose, treat, and understand lung cancer,” said Min-Han Tan, Founding CEO and Medical Director at Lucence. “Lucence is committed to leveraging our ultrasensitive amplicon-based liquid biopsy technology, AmpliMark, to harvest as much actionable molecular information to help patients at every stage of their journey.”
Lucence recently announced the publication of a validation study for its flagship LiquidHALLMARK ctDNA Liquid Biopsy Assay. The study, published in PLOS ONE, establishes LiquidHALLMARK’s performance and identifies actionable biomarkers in 70% of lung cancer patients. In addition to showing high sensitivity of both LiquidHALLMARK and Lucence’s AmpliMark amplicon next-generation sequencing (NGS) platform, external validation with cobas® EGFR Mutation Test v2 for lung cancer specimens demonstrated an overall concordance of 84.00% with a 100% concordance rate for EGFR variants above 0.4% VAF.
Abstracts to be presented in poster presentations at the conference build on Lucence’s continued innovation in liquid biopsy in the detection, treatment, and monitoring of lung cancer.
- Sensitive Detection of Lung Cancer Using a Multiomic Plasma Cell-Free DNA Sequencing Assay, #2347
A novel combinatorial AmpliMARK-based test measuring ctDNA abundance, cfDNA fragmentation profiles, and cfDNA methylation demonstrated an overall sensitivity of 85% and specificity of 95% for the detection of lung cancer. 14.3% additional lung cancer cases were detected compared to ctDNA detection alone, demonstrating the utility of a multi-signal cfDNA approach for sensitive detection of lung cancer.
- Retrospective Analysis of BRCA1/2 Alterations in Advanced NSCLC Using An Amplicon-based NGS Liquid Biopsy Assay, #2472
Lucence’s AmpliMark-powered LiquidHALLMARK assay detected pathogenic BRCA1/2 alterations in the plasma ctDNA of 6.7% (19/285) of metastatic NSCLC patients. BRCA-mutant NSCLC had more somatic mutations and higher plasma cfDNA concentrations compared to BRCA-wildtype NSCLC, highlighting BRCA as a potential biomarker for inclusion in lung liquid biopsy testing.
- Peripheral T-Cell Receptor Repertoire Profiling in Non-small Cell Lung Cancer Using an Amplicon-Based Sequencing Assay, #2293
Characterization of NSCLC patient peripheral T-cell receptor repertoire (TCR) using Lucence’s AmpliMark platform shows differences in TCR repertoires by molecular subtypes of NSCLC and treatment status, suggesting that TCR-sequencing can complement plasma-based cfDNA sequencing in treatment selection and monitoring.